Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Available from: www.goldcopd.org. Published 2019Accessed November 19, 2018
   Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterolglycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNReduction in all-cause mortality with single inhaler triple therapy (FF/UMEC/VI) versus dual therapy (FF/VI and UMEC/VI) in symptomatic patients with COPD: prespeci-fied analysis of the Phase III IMPACT TrialAm J Respir Crit Care Med2018197A1015
   Google Scholar
• VestboJFabbriLPapiAInhaled corticosteroid containing combinations and mortality in COPDEur Respir J20181801230
   Google Scholar
• Standards for the diagnosis and care of patients with chronic obstructive pulmonary diseaseAmerican Thoracic SocietyAm J Respir Crit Care Med19951525 Pt 2S77S1217582322
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• HohlfeldJMVogel-ClaussenJBillerHEffect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trialLancet Respir Med20186536837829477448
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med2005143531732616144890
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEECardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysisChest200412562309232115189956
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDReviewASInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• GershonACroxfordRCalzavaraACardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary diseaseJAMA Intern Med2013173131175118523689820
   PubMed Web of Science ®Google Scholar
• WilcheskyMErnstPBrophyJMPlattRWSuissaSBronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort studyChest2012142229830422871755
   PubMed Web of Science ®Google Scholar
• WilcheskyMErnstPBrophyJMPlattRWSuissaSBronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohortChest2012142230531122871756
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBCardiovascular events in patients with COPD: TORCH study resultsThorax201065871972520685748
   PubMed Web of Science ®Google Scholar
• SuissaSDell’anielloSErnstPLong-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary eventsChest20171511606727554300
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMKestenSMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20091801094895519729663
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJABrookRDFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182627203508
   PubMed Web of Science ®Google Scholar
• ObaYSarvaSTDiasSEfficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
   PubMed Web of Science ®Google Scholar
• SuissaSDell’AnielloSErnstPConcurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular eventsEur Respir J2017495160224528536251
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAnzuetoARCarterKTiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trialLancet Respir Med20186533734429605624
   PubMed Web of Science ®Google Scholar
• No authors listedStandards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986Am Rev Respir Dis198713612252443605835
   PubMed Web of Science ®Google Scholar
• BrownHMStoreyGGeorgeWHBeclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthmaBr Med J1972158005855904335298
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPMAJenkinsCRHurdSSGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116351256127611316667
   PubMedGoogle Scholar
• CelliBRMacNeeWATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• BurrowsBBloomJWTraverGAClineMGThe course and prognosis of different forms of chronic airways obstruction in a sample from the general populationN Engl J Med198731721130913143683459
   PubMed Web of Science ®Google Scholar
• KerstjensHABrandPLHughesMDA comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study GroupN Engl J Med199232720141314191357553
   PubMed Web of Science ®Google Scholar
• DjukanovićRWilsonJWBrittenKMEffect of an inhaled corticosteroid on airway inflammation and symptoms in asthmaAm Rev Respir Dis199214536696741546849
   PubMed Web of Science ®Google Scholar
• FabbriLMRomagnoliMCorbettaLDifferences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2003167341842412426229
   PubMed Web of Science ®Google Scholar
• PauwelsRALöfdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med1999340251948195310379018
   PubMed Web of Science ®Google Scholar
• VestboJSørensenTLangePBrixATorrePViskumKLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet199935391671819182310359405
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research GroupWiseRConnettJWeinmannGScanlonPSkeansMEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
   PubMed Web of Science ®Google Scholar
• JonesPWWillitsLRBurgePSCalverleyPMAInhaled steroids in obstructive lung disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbationsEur Respir J2003211687312570111
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD003794
   PubMed Web of Science ®Google Scholar
• SorianoJBVestboJPrideNBKiriVMadenCMaierWCSurvival in COPD patients after regular use of fluticasone propionate and salmeterol in general practiceEur Respir J200220481982512412670
   PubMed Web of Science ®Google Scholar
• SinDDTuJVInhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164458058411520719
   PubMed Web of Science ®Google Scholar
• IannellaHLunaCWatererGInhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated reviewTher Adv Respir Dis201610323525526893311
   PubMed Web of Science ®Google Scholar
• FergusonGTTashkinDPSkärbyTEffect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) studyRespir Med2017132314129229103
   PubMed Web of Science ®Google Scholar
• MiravitllesMSoler-CataluñaJJCalleMSpanish COPD Guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary diseaseArch Bronconeumol (English Ed)2017536324335
   PubMed Web of Science ®Google Scholar
• PostmaDSRabeKFThe asthma–COPD overlap syndromeN Engl J Med2015373131241124926398072
   PubMed Web of Science ®Google Scholar
• GershonASCampitelliMACroxfordRCombination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary diseaseJAMA2014312111114112125226477
   PubMed Web of Science ®Google Scholar
• BafadhelMPavordIDRussellREKEosinophils in COPD: just another biomarker?Lancet Respir Med20175974775928601554
   PubMed Web of Science ®Google Scholar
• ChapmanKRHurstJRFrentSMLong-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med2018198332933929779416
   PubMed Web of Science ®Google Scholar
• CalverleyPMATetzlaffKVogelmeierCEosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201719691219122128306321
   PubMed Web of Science ®Google Scholar
• RabeKFBeghéBFabbriLMPeripheral eosinophil count as a biomarker for the management of COPD: not there yetEur Respir J2017505170216529167308
   PubMed Web of Science ®Google Scholar
• HartjesFJVonkJMFaizAPredictive value of eosinophils and neutrophils on clinical effects of ICS in COPDRespirology201823111023103129696728
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSAnzuetoABarnesNBlood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysisLancet Respir Med20164973174127460163
   PubMed Web of Science ®Google Scholar
• PavordIDChanezPCrinerGJMepolizumab for eosinophilic chronic obstructive pulmonary diseaseN Engl J Med2017377171613162928893134
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Available from: www.goldcopd.org. Published 2017Accessed December 21, 2016
   Google Scholar
• SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax200863759259818245142
   PubMed Web of Science ®Google Scholar
• JungKSParkHYParkSYComparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled studyRespir Med2012106338238921975275
   PubMed Web of Science ®Google Scholar
• HananiaNACraterGDMorrisANEmmettAHO’DellDMNiewoehnerDEBenefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPDRespir Med201210619110122040533
   PubMed Web of Science ®Google Scholar
• FrithPAThompsonPJRatnavadivelRGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialThorax201570651952725841237
   PubMed Web of Science ®Google Scholar
• SilerTMKerwinESingletaryKBrooksJChurchAEfficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studiesCOPD201613111026451734
   PubMedGoogle Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar
• LeeSDXieCMYunusFEfficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East AsiaRespirology201621111912726394882
   PubMed Web of Science ®Google Scholar
• SilerTMKerwinETombsLFahyWANayaITriple therapy of umeclidinium + inhaled corticosteroids/long-acting beta2 agonists for patients with COPD: pooled results of randomized placebo-controlled trialsPulm Ther2016214358
   Google Scholar
• ShortPMWilliamsonPAElderDHJLipworthSIWSchembriSLipworthBJThe impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPDChest20121411818621799028
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis20151012207221726527869
   PubMed Web of Science ®Google Scholar
• SimeoneJCLuthraRKailaSInitiation of triple therapy maintenance treatment among patients with COPD in the USInt J Chron Obstruct Pulmon Dis201712738328053518
   PubMed Web of Science ®Google Scholar
• MiyazakiMNakamuraHTakahashiSThe reasons for triple therapy in stable COPD patients in Japanese clinical practiceInt J Chron Obstruct Pulmon Dis2015101053105926082629
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFCalverleyPMADeterminants of response to roflumilast in severe COPD: pooled analysis of two randomized trialsAm J Respir Crit Care Med2018198101268127829763572
   PubMed Web of Science ®Google Scholar
• SinghDPapiAVezzoliSCHF5993 pMDI (extrafine beclometasone dipropionate:BDP, formoterol fumarate:FF, glycopyrronium bromide:GB) reduces clinically important deteriorations (CID) in COPD: post-hoc analysis of TRILOGY studyEur Respir J201750Suppl 61PA533
   Google Scholar
• SinghDFabbriLPapiAExtrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITYEur Respir J201750Suppl 61OA2898
   Google Scholar
• SinghDPapiAVezzoliSEffect of CHF5993 pMDI (extrafine beclometasone dipropionate:BDP, formoterol fumarate:FF, glycopyrronium bromide: GB) on clinically important deteriorations (CID) in COPD: post-hoc analysis of TRINITY studyEur Respir J201750Suppl 61PA3949
   Google Scholar
• ScuriMSinghDFabbriLMSingle inhaler extrafine triple therapy reduces clinically important deterioration (CID) in COPD compared to indacaterol/glycopyrronium: post-hoc analysis of the TRIBUTE studyAm J Respir Crit Care Med2018197A1013
   Web of Science ®Google Scholar
• ScuriMSinghDFabbriLMSingle inhaler extrafine triple therapy improves clinical outcomes in GOLD B COPD patients: post-hoc analysis of the TRIBUTE studyAm J Respir Crit Care Med2018197A3041
   Google Scholar
• ScuriMSinghDFabbriLMRisk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol/glycopyrronium: post-hoc analysis of the TRIBUTE studyAm J Respir Crit Care Med2018197A3030
   Web of Science ®Google Scholar
• SuissaSDrazenJMMaking sense of triple inhaled therapy for COPDN Engl J Med2018378181723172429669218
   PubMed Web of Science ®Google Scholar
• JansonCStratelisGMiller-LarssonAHarrisonTWLarssonKScientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPDInt J Chron Obstruct Pulmon Dis2017123055306429089754
   PubMed Web of Science ®Google Scholar
• SonnappaSMartinRIsraelERisk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroidsPLoS One2017126e017811228617814
   PubMed Web of Science ®Google Scholar
• VanfleterenLUllmanAFabbriLMTime for a longer and better life for patients with COPDEur Respir J2018511170256929326323
   PubMed Web of Science ®Google Scholar
• FergusonGTRabeKFMartinezFJTriple therapy with budes-onide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trLancet Respir Med201861074775830232048
   PubMed Web of Science ®Google Scholar